An optimized RFFL-targeting ASO enhanced the efficacy of CFTR modulators by increasing the functional PM expression of ΔF508-CFTR in primary human bronchial epithelial (CF-HBE) cells derived from CF patients. This evidence concerns the gene CFTR and cystic fibrosis.